CTLA4

[Nature Communications] The authors combined transcriptional and epigenetic profiling to identify a human effector Treg cell signature.

[Nature Reviews Endocrinology] Investigators review the current understanding of the pathobiology, clinical manifestations and treatment approaches to endocrine toxicities arising from immune checkpoint inhibitors.

[Frontiers in Immunology] CTLA4-chimeric antigen receptor T cells were found to accumulate in tumors and are toxic to myeloid-derived suppressor cells without signs of severe GVHD and CRS in preclinical models.

[Nature Communications] By assessing multiple discrete areas across multiple metastases, the authors found a high level of intra-patient homogeneity with respect to tumor phenotype.

[Nature Reviews Clinical Oncology] Using the structure provided by the well-described cancer–immunity cycle, scientists outline the key steps required for a successful antitumour immune response in the context of renal cell carcinoma, and describe the development of promising new immunotherapies within the context of this framework.

[British Journal of Dermatology] Investigators review the clinical presentations of cutaneous immune‐related adverse effects associated with checkpoint inhibitor therapy in adult patients with metastatic malignant melanoma.